Status:
WITHDRAWN
Esomeprazole Versus Pantoprazole to Prevent Peptic Ulcer Rebleeding
Lead Sponsor:
Lotung Poh-Ai Hospital
Collaborating Sponsors:
Tomorrow Medical Foundation
Conditions:
Peptic Ulcer
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The aim of this study is to compare the clinical effectiveness of intravenous esomeprazole and pantoprazole in preventing recurrent bleeding in the patients with high-risk bleeding peptic ulcers after...
Detailed Description
Endoscopic hemostasis and proton pump inhibitor (PPI) constitute the cornerstone in the management of peptic ulcer bleeding (PUB), which remains a prevalent disorder associated with substantial morbid...
Eligibility Criteria
Inclusion
- aged more than 18 years
- undergo emergent endoscopy within 24 hours of presentation
- have peptic ulcers in the gastroesophageal junction, stomach, or duodenum
- high-risk stigmata of peptic ulcers: Forrest classification IA\~IIB
- endoscopic hemostasis by thermocoagulation or clip placement
Exclusion
- pregnant or lactating
- written informed consent not obtained
- initial endoscopic hemostasis fail
- bleeding tendency (platelet count \< 50×109/L, prolonged prothrombin time for more than 3 seconds, or were taking anticoagulants)
- PPI use within 14 days of enrollment
- comorbid with severe hepatic or renal insufficiency (serum total bilirubin more than 5 mg/dL, serum creatinine more than 5 mg/dL, or under dialysis)
- bleeding gastric cancers
Key Trial Info
Start Date :
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00881413
Last Update
April 8 2015
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.